PMID- 36456125
OWN - NLM
STAT- MEDLINE
DCOM- 20221205
LR  - 20221205
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 12
DP  - 2022 Dec
TI  - Safety and Efficacy of Palliative Radiotherapy (25 Gy x 5 Fractions) for 
      Symptomatic Pelvic Tumors.
PG  - 6099-6103
LID - 10.21873/anticanres.16122 [doi]
AB  - BACKGROUND/AIM: Palliative radiotherapy is one of the effective treatments for 
      pelvic tumors with bleeding or pain. In this study, we evaluated the safety and 
      efficacy of palliative radiotherapy (RT) for symptomatic pelvic tumors when 
      delivered as 25 Gy in 5 fractions. PATIENTS AND METHODS: We retrospectively 
      analyzed 34 patients (gynecological cancer: n=14, rectal cancer: n=5, metastatic 
      pelvic bone tumor: n=7, metastatic pelvic lymph node tumor: n=5, synovial sarcoma 
      of the pelvis: n=1, prostate cancer: n=1, and urothelial cancer: n=1), who were 
      treated between July 2016 and July 2021. The symptoms were bleeding in 16 
      patients, pain in 17 patients, and both bleeding and pain in 1 patient. The 
      hemostatic effect of RT was evaluated with pre- and post-treatment hemoglobin 
      (Hb) values. If the Hb levels reached a nadir and increased thereafter, we 
      considered that there is a hemostatic response. The pain was evaluated with a 
      numerical rating scale (NRS) and treatment response was defined as a decrease in 
      NRS. RESULTS: Their median follow-up period was 4 months. A hemostatic response 
      was observed in 82% of patients (14 of 17 patients). A pain relief response was 
      observed in 78% of patients (14 of 18 patients). Acute adverse effects (AEs) 
      included grade 1 diarrhea (n=3), grade 1 dermatitis (n=1) and grade 1 urinary 
      frequency (n=1); late AEs have not been observed so far. CONCLUSION: 25 Gy of 
      palliative RT in 5 fractions seems to be safe and effective for symptomatic 
      pelvic tumors, similar to conventional palliative RT schedules.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Aoshika, Tomomi
AU  - Aoshika T
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Abe, Takanori
AU  - Abe T
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan mrtaka100@yahoo.co.jp.
FAU - Iino, Misaki
AU  - Iino M
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Saito, Satoshi
AU  - Saito S
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Ryuno, Yasuhiro
AU  - Ryuno Y
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Ohta, Tomohiro
AU  - Ohta T
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Igari, Mitsunobu
AU  - Igari M
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Hirai, Ryuta
AU  - Hirai R
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Kumazaki, Y U
AU  - Kumazaki YU
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Noda, Shin-Ei
AU  - Noda SE
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
FAU - Kato, Shingo
AU  - Kato S
AD  - Department of Radiation Oncology, International Medical Center, Saitama Medical 
      University, Saitama, Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Hemostatics)
SB  - IM
MH  - Male
MH  - Humans
MH  - *Pelvic Neoplasms/radiotherapy
MH  - Retrospective Studies
MH  - *Radiation Oncology
MH  - Pain
MH  - *Hemostatics
MH  - *Neoplasms, Second Primary
OTO - NOTNLM
OT  - 25 Gy/5 fr
OT  - Palliative radiotherapy
OT  - pelvic tumors
EDAT- 2022/12/02 06:00
MHDA- 2022/12/06 06:00
CRDT- 2022/12/01 21:13
PHST- 2022/10/27 00:00 [received]
PHST- 2022/11/04 00:00 [revised]
PHST- 2022/11/08 00:00 [accepted]
PHST- 2022/12/01 21:13 [entrez]
PHST- 2022/12/02 06:00 [pubmed]
PHST- 2022/12/06 06:00 [medline]
AID - 42/12/6099 [pii]
AID - 10.21873/anticanres.16122 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Dec;42(12):6099-6103. doi: 10.21873/anticanres.16122.